LncRNA NORAD Stimulates Proliferation and Migration of Renal Cancer Via Activating the MiR-144-3p/MYCN Axis
Overview
Pharmacology
Toxicology
Affiliations
Objective: The purpose of this study was to clarify the potential role of long non-coding RNA (lncRNA) NORAD in the development of renal cancer.
Patients And Methods: Expression levels of NORAD, miR-144-3p, and MYCN in renal cancer tissues and cell lines were detected. After overexpression of NORAD, proliferative and migratory changes in ACHN and A498 cells were evaluated by Cell Counting Kit-8 (CCK-8) and transwell assay, respectively. Thereafter, Luciferase assay was conducted to determine the interaction in the NORAD/miR-144-3p/MYCN axis. Besides, its biological function in influencing phenotype changes of renal cancer cells was finally demonstrated by rescue experiments.
Results: The results manifested that NORAD and MYCN were upregulated, while miR-144-3p was downregulated in renal cancer tissues. Overexpression of NORAD stimulated proliferative and migratory potentials in ACHN and A498 cells, which were partially abolished by co-overexpression of miR-144-3p. Moreover, NORAD/miR-144-3p/MYCN axis was found to be responsible for stimulating the malignant development of renal cancer.
Conclusions: LncRNA NORAD stimulates proliferative and migratory potentials in renal cancer by sponging miR-144-3p to upregulate MYCN.
Liu L, Guo J, Pang X, Shang W, Wang Z, Wang J Ren Fail. 2023; 45(1):2147083.
PMID: 36748746 PMC: 9930837. DOI: 10.1080/0886022X.2022.2147083.
The Potential of NORAD-PUMILIO- Regulatory Axis as a Biomarker in Breast Cancer.
Muller C, Giner I, Zambalde E, Mingorance Carvalho T, Ribeiro E, de Oliveira J Noncoding RNA. 2022; 8(6).
PMID: 36412911 PMC: 9680495. DOI: 10.3390/ncrna8060076.
lncRNA NORAD promotes lung cancer progression by competitively binding to miR-28-3p with E2F2.
Mao W, Wang S, Chen R, He Y, Lu R, Zheng M Open Med (Wars). 2022; 17(1):1538-1549.
PMID: 36245705 PMC: 9520332. DOI: 10.1515/med-2022-0538.
Liu Q, Zhao H, Guo Y, Zhang K, Shang F, Liu T J Healthc Eng. 2022; 2022:7904982.
PMID: 36105715 PMC: 9467764. DOI: 10.1155/2022/7904982.
Feng D, Li Z, Yang L, Liang H, He H, Liu L Oxid Med Cell Longev. 2022; 2022:8825784.
PMID: 35281474 PMC: 8906129. DOI: 10.1155/2022/8825784.